登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases
ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由山东省肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07062055,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 70 岁;性别:不限
登记记录的入选字段
Unresectable HCC, BCLC Stage C according to the BCLC strategy-2026 update, with staging established via biopsy pathology and/or clinical diagnosis.
入选标准第 2 条
Received targeted-immunotherapy for HCC (e.g., PD-(L)1 inhibitors + tyrosine kinase inhibitors (TKIs))
排除标准第 13 条
Prior immunotherapy: anti-PD-(L)1/CTLA-4 or chimeric antigen receptor T-cell therapy
排除标准第 14 条
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤5 × upper limit of normal (ULN); total bilirubin <3 × ULN; serum albumin ≥28 g/L
入选标准第 18 条
Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min
入选标准第 19 条
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤1.5 × ULN
入选标准第 21 条
≥1 measurable lesion (per RECIST 1.1):
入选标准第 9 条
Tumor: ≥10 mm (CT long axis)
入选标准第 10 条
Lymph node: ≥15 mm (CT short axis)
入选标准第 11 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);日常活动能力;试验排除的其他疾病;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07062055,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Male or female patients aged between 18 and 70 years. Unresectable HCC, BCLC Stage C according to the BCLC strategy-2026 update, with staging established via biopsy pathology and/or clinical diagnosis. Child-Pugh class A without clinically significant hepatic decompensation; Eastern Cooperative Oncology Group (ECOG) performance status 0-1 Metastatic burden and local therapy eligibility Extrahepatic oligometastatic disease defined as ≤3 involved organs with ≤5 total metastatic lesions All intended intrahepatic and/or extrahepatic SBRT targets must satisfy protocol-specified target-coverage, liver reserve, and organ-at-risk (OAR) constraints within a composite 5-fraction plan Prognosis \& measurable disease Life expectancy ≥3 months ≥1 measurable lesion (per RECIST 1.1): Tumor: ≥10 mm (CT long axis) Lymph node: ≥15 mm (CT short axis) Prior therapy Prior locoregional therapy permitted:radiofrequency ablation (RFA), TACE, or HAIC, provided that: Documented radiographic progression or intolerance after the prior therapy Washout ≥28 days Treatment-related toxicities recovered to ≤Grade 1 (alopecia and peripheral neuropathy ≤Grade 2 allowed) Laboratory and virologic requirements Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤5 × upper limit of normal (ULN); total bilirubin <3 × ULN; serum albumin ≥28 g/L Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min Urine dipstick protein <2+; if baseline dipstick proteinuria is ≥2+, 24-hour urinary protein must be <1 g International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤1.5 × ULN排除标准:Exclusion Criteria:
Histopathological exclusions Mixed HCC subtypes: Fibrolamellar HCC or sarcomatoid HCC or cholangiocarcinoma components Curative local therapy candidacy Current candidacy for resection, liver transplant, or RFA RT infeasibility Prior radioembolization Single liver tumor ≥15 cm or total intrahepatic tumor diameter ≥20 cm more than 5 discrete intrahepatic parenchymal foci are present direct tumor extension into the stomach, duodenum, small bowel, or large bowel measurable common or main-branch biliary duct involvement Prior liver radiotherapy that would result in excessive overlap with the planned treatment fields Prior systemic therapies Received targeted-immunotherapy for HCC (e.g., PD-(L)1 inhibitors + tyrosine kinase inhibitors (TKIs)) Prior immunotherapy: anti-PD-(L)1/CTLA-4 or chimeric antigen receptor T-cell therapy Hemorrhage/portal hypertension and hepatic decompensation risk Variceal bleeding within 6 months. Untreated or high-risk esophagogastric varices (e.g., grade ≥2 on endoscopy within 3 months) or other clinical evidence of portal hypertension with high bleeding risk per investigator. Moderate or severe ascites History of or active hepatic encephalopathy History of hemoptysis (≥2.5 mL of bright red blood per episode) within 28 days before study treatment Evidence of bleeding diathesis or significant coagulopathy Current or recent (within 10 days before study treatment) use of aspirin (≥325 mg/day), dipyridamole, ticlopidine, clopidogrel, cilostazol, or therapeutic-dose oral/parenteral anticoagulants or thrombolytic agents Allergy to any component of iparomlimab/tuvonralimab or bevacizumab Comorbidities Active autoimmune disease or a history of autoimmune or inflammatory disease that may relapse; exceptions include hypothyroidism controlled with hormone replacement only, controlled celiac disease, and skin disorders not requiring systemic treatment (e.g., vitiligo, psoriasis, or alopecia) Any condition requiring systemic corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressive medication within 14 days before study treatment Active or uncontrolled infection, including tuberculosis, or known HIV infection Prior allogeneic stem cell transplantation or organ transplantation Inadequately controlled hypertension, defined as systolic blood pressure ≥150 mmHg and/or diastolic blood pressure >90 mmHg despite optimal medical management, or a history of hypertensive crisis or hypertensive encephalopathy History within 6 months before study treatment of myocardial infarction, unstable angina, symptomatic heart failure (New York Heart Association class ≥II), cerebrovascular accident, transient ischemic attack, pulmonary embolism, deep vein thrombosis, or other serious thromboembolic events Major surgical procedure within 28 days before study treatment, or serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture History within 6 months before study treatment of gastrointestinal perforation, abdominal or tracheoesophageal fistula, or intra-abdominal abscess
引自 ClinicalTrials.gov, NCT07062055, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07062055,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。